AMRX - Amneal Pharmaceuticals, Inc.
NEXT EARNINGS:
Feb 27, 2026
(in 3 days)
EPS Est: $0.17
|
Rev Est: $806.1M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$15.00
DETAILS
HIGH:
$15.00
LOW:
$15.00
MEDIAN:
$15.00
CONSENSUS:
$15.00
UPSIDE:
2.32%
Market Cap:
4.61B
Volume:
992,243
Avg Volume:
2,479,970
52 Week Range:
6.685-15.42
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Beta:
1.35
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
8,300
IPO Date:
2018-05-07
EPS (TTM):
-0.38
P/E Ratio:
-20.94
Revenue (TTM):
2.79B
Total Assets:
3.50B
Total Debt:
2.59B
Cash & Equiv:
110.55M
Rev Growth (5Y):
11.4%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
20.9%
ROCE:
8.6%
Debt/Equity:
-23.73
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-10-30 | $0.17 | $0.13 | +30.8% | $784.5M | $806.1M | -2.7% |
| 2025-08-05 | $0.25 | $0.18 | +38.9% | $724.5M | $768.6M | -5.7% |
| 2025-05-02 | $0.21 | $0.15 | +40.0% | $695.4M | $744.2M | -6.6% |
| 2025-02-28 | $0.12 | $0.15 | -20.0% | $730.5M | $723.1M | +1.0% |
| 2024-11-08 | $0.16 | $0.13 | +23.1% | $702.5M | $700.8M | +0.2% |
| 2024-08-09 | $0.16 | $0.14 | +14.3% | $701.8M | $658.1M | +6.6% |
| 2024-05-03 | $0.14 | $0.09 | +55.6% | $659.2M | — | — |
| 2024-03-01 | $0.14 | $0.07 | +100.0% | $617.0M | $663.6M | -7.0% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.79B | 2.39B | 2.21B | 2.09B | 1.99B | 1.63B | 1.66B | 1.03B | 1.02B | 866.28M | 785.62M |
| Net Income | (116.89M) | (83.99M) | (129.99M) | 10.62M | 91.06M | (361.92M) | (169.73M) | 167.65M | 207.38M | 169.45M | 176.93M |
| EPS | -0.38 | -0.48 | -0.86 | 0.07 | 0.62 | -4.57 | -1.33 | 1.46 | 1.10 | 0.90 | 0.94 |
| Total Assets | 3.50B | 3.47B | 3.80B | 3.94B | 4.01B | 3.67B | 4.35B | 1.34B | 1.22B | 1.01B | N/A |
| Total Debt | 2.59B | 2.75B | 2.85B | 2.88B | 3.00B | 2.77B | 2.69B | 1.48B | 1.20B | 1.01B | N/A |
| Cash & Equivalents | 110.55M | 91.54M | 25.98M | 247.79M | 341.38M | 151.20M | 213.39M | 74.17M | 27.37M | 61.09M | N/A |
| Operating Cash Flow | 295.10M | 345.58M | 65.10M | 241.82M | 379.00M | 1.71M | 250.23M | 234.19M | 115.06M | 104.88M | 112.26M |
| Free Cash Flow | 220.11M | 276.39M | (25.50M) | 194.09M | 317.16M | (95.73M) | 153.14M | 119.92M | (9.55M) | (12.50M) | 32.87M |
| FCF per Share | 0.71 | 1.58 | -0.17 | 1.30 | 2.12 | -0.72 | 1.20 | 1.04 | -0.05 | -0.07 | 0.17 |
| Book Value | (109.27M) | 19.78M | 298.42M | 360.34M | 303.27M | 232.01M | 896.36M | (385.74M) | (185.29M) | (195.14M) | N/A |
| Cash & ST Investments | 112.42M | 93.74M | 27.80M | 247.79M | 343.07M | 152.32M | 213.39M | 74.17M | 31.72M | 66.06M | N/A |
| ROC Equity | N/A | -4.25 | -0.44 | 0.03 | 0.30 | -1.56 | -0.19 | N/A | N/A | N/A | N/A |